Clinical Trials for Thyroid Carcinoma: Past, Present, and Future
关键词: Thyroid carcinoma 、 Pathology 、 Medicine 、 Family medicine 、 Thyroid 、 Clinical care 、 State of affairs 、 Clinical trial 、 Medical literature 、 Thyroid cancer
摘要: meeting of the American Thyroid Association on selected topic “Multicenter Clinical Trials in Cancer.” The assigned task was to summarize state field and identify both challenges opportunities for advancement improved clinical care outcomes our patients. Surveying medical literature last quarter 20th century preparation that lecture led certain obvious yet unsatisfying conclusions about affairs 1999:
springer.com
sci-hub.se 参考文章(19)
SD Williams, R Birch, LH Einhorn, None, Phase II evaluation of doxorubicin plus cisplatin in advanced thyroid cancer: a Southeastern Cancer Study Group Trial. Cancer treatment reports. ,vol. 70, pp. 405- 407 ,(1986)
, Steven I. Sherman, James D. Brierley, Matthew Sperling, Kenneth B. Ain, S. Thomas Bigos, David S. Cooper, Bryan R. Haugen, Mona Ho, Irwin Klein, Paul W. Ladenson, Jacob Robbins, Douglas S. Ross, Bonny Specker, Terry Taylor, Harry R. Maxon, Prospective multicenter study of thyroid carcinoma treatment initial analysis of staging and outcome Cancer. ,vol. 83, pp. 1012- 1021 ,(1998) , 10.1002/(SICI)1097-0142(19980901)83:5<1012::AID-CNCR28>3.0.CO;2-9
John Laszlo, The Cure of Childhood Leukemia: Into the Age of Miracles ,(1995)
Steven I. Sherman, Staging of thyroid carcinoma-reply Cancer. ,vol. 83, pp. 848- 850 ,(1998) , 10.1002/(SICI)1097-0142(19980901)83:5<848::AID-CNCR7>3.0.CO;2-E
Katsutaro Shimaoka, David A. Schoenfeld, William D. Dewys, Richard H. Creech, Ronald Deconti, A randomized trial of doxorubicin versus doxorubicin plus cisplatin in patients with advanced thyroid carcinoma Cancer. ,vol. 56, pp. 2155- 2160 ,(1985) , 10.1002/1097-0142(19851101)56:9<2155::AID-CNCR2820560903>3.0.CO;2-E
N. J. Sarlis, L. Gourgiotis, Molecular elements of apoptosis-regulating pathways in follicular thyroid cells: mining for novel therapeutic targets in the treatment of thyroid carcinoma. Current Drug Targets - Immune, Endocrine & Metabolic Disorders. ,vol. 4, pp. 187- 198 ,(2004) , 10.2174/1568008043339866
Elihu H. Estey, Peter F. Thall, New designs for phase 2 clinical trials Blood. ,vol. 102, pp. 442- 448 ,(2003) , 10.1182/BLOOD-2002-09-2937
Milena Braga-Basaria, Matthew D. Ringel, Beyond Radioiodine: A Review of Potential New Therapeutic Approaches for Thyroid Cancer The Journal of Clinical Endocrinology and Metabolism. ,vol. 88, pp. 1947- 1960 ,(2003) , 10.1210/JC.2002-021863
Juri Gelovani Tjuvajev, Ronald G Blasberg, In vivo imaging of molecular-genetic targets for cancer therapy Cancer Cell. ,vol. 3, pp. 327- 332 ,(2003) , 10.1016/S1535-6108(03)00082-5
Brian J. Druker, Nicholas B. Lydon, Lessons learned from the development of an Abl tyrosine kinase inhibitor for chronic myelogenous leukemia Journal of Clinical Investigation. ,vol. 105, pp. 3- 7 ,(2000) , 10.1172/JCI9083